FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 339:44-45 July 2, 1998 Number 1 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Miller, T. P. PubMed Citation

The search for the optimal treatment for localized intermediate- and high-grade non-Hodgkin's lymphoma has progressed through several phases in recent decades. In the 1960s and early 1970s, irradiation had a prominent, if not exclusive, role. However, radiation oncologists soon had to admit that the results achieved by irradiation alone were not satisfactory.¹ In the early 1980s, a number of oncologists, carrying matters to the other extreme, advocated chemotherapy alone for localized lymphomas with unfavorable histologic features.²

Since then, the issue of how to treat localized intermediate- and high-grade non-Hodgkin's lymphoma has divided the world of lymphoma specialists into three parts. . . . [Full Text of this Article]

References

Related Letters:

Treatment of Intermediate-Grade and High-Grade Non-Hodgkin's Lymphoma
Wirth A., Prince H. M., Wolf M., Machida U., Kami M., Hirai H., Mounier N., Gisselbrecht C., Lepage E., Kosmas C., Malamos N. A., Antonopoulos M. J., Decaudin D., Miller T. P., LeBlanc M., Fisher R. I., The Southwest Oncology Group
Extract | Full Text  
N Engl J Med 1998; 339:1475-1477, Nov 12, 1998. Correspondence

This article has been cited by other articles:

• Wirth, A., Prince, H. M., Wolf, M., Machida, U., Kami, M., Hirai, H., Mounier, N., Gisselbrecht, C., Lepage, E., Kosmas, C., Malamos, N. A., Antonopoulos, M. J., Decaudin, D., Miller, T. P., LeBlanc, M., Fisher, R. I., The Southwest Oncology Group, (1998). Treatment of Intermediate-Grade and High-Grade Non-Hodgkin's Lymphoma. NEJM 339: 1475-1477 [Full Text]